Cargando…

The sub-molecular characterization identification for cervical cancer

BACKGROUND: The efficacy of therapy in cervical cancer (CESC) is blocked by high molecular heterogeneity. Thus, the sub-molecular characterization remains primarily explored for personalizing the treatment of CESC patients. METHODS: Datasets with 741 CESC patients were obtained from TCGA and GEO dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, XinKai, Wang, Na, He, Zanjing, Kang, Wenjun, Wang, Lu, Han, Xia, Yang, Liu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360967/
https://www.ncbi.nlm.nih.gov/pubmed/37484385
http://dx.doi.org/10.1016/j.heliyon.2023.e16873
_version_ 1785076130382872576
author Mo, XinKai
Wang, Na
He, Zanjing
Kang, Wenjun
Wang, Lu
Han, Xia
Yang, Liu
author_facet Mo, XinKai
Wang, Na
He, Zanjing
Kang, Wenjun
Wang, Lu
Han, Xia
Yang, Liu
author_sort Mo, XinKai
collection PubMed
description BACKGROUND: The efficacy of therapy in cervical cancer (CESC) is blocked by high molecular heterogeneity. Thus, the sub-molecular characterization remains primarily explored for personalizing the treatment of CESC patients. METHODS: Datasets with 741 CESC patients were obtained from TCGA and GEO databases. The NMF algorithm, random forest algorithm, and multivariate Cox analysis were utilized to construct a classifier for defining the sub-molecular characterization. Then, the biological characteristics, genomic variations, prognosis, and immune landscape in molecular subtypes were explored. The significance of classifier genes was validated by quantitative Real-Time PCR, cell transfection, cell colony formation assay, wound healing assay, cell proliferation assay, and Western blot. RESULTS: The CESC patients were classified into two subtypes, and the high classifier-score patients with significant differences in ECM-receptor interaction, PI3K-Akt signaling pathway, and MAPK signaling pathway showed a poorer prognosis in OS (p < 0.001), DFI (p = 0.016), PFI (p < 0.001) and DSS (p < 0.001), and with high the M0 Macrophage and resting Mast cells infiltration and low HLA family gene expression. Moreover, the constructed classifier owns a high identified accuracy in the tumor/normal groups (AUC: 0.993), the tumor/CIN1–CIN3 groups (AUC: 0.963), and normal/CIN1–CIN3 groups (AUC: 0.962), and the total prediction performance is better than currently published signatures in CESC (C−index: 0,763). The combined prediction performance further indicated that Nomogram (AUC = 0.837) is superior to the classifier (AUC = 0.835) and Stage (AUC = 0.568), and the C−index of calibration curves is 0.784. The potential biological function of classifier genes indicated that silencing GALNT2 inhibited the cancer cell's proliferation, migration, and colony formation; Conversely, the cancer cell's proliferation, migration, and colony formation were increased after the upregulation of GALNT2. The Epithelial-Mesenchymal Transition Experiment showed that GALNT2 knockdown might reduce the levels of Snail and Vimentin proteins and increase E-cadherin; Conversely, the levels of Snail and Vimentin proteins were increased, E-cadherin was reduced by GALNT2 upregulation. CONCLUSION: The classifier we constructed may help improve our understanding of subtype characteristics and provide a new strategy for developing CESC therapeutics. Remarkably, GALNT2 may be an option to directly target drivers in CESC cancer therapy.
format Online
Article
Text
id pubmed-10360967
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103609672023-07-22 The sub-molecular characterization identification for cervical cancer Mo, XinKai Wang, Na He, Zanjing Kang, Wenjun Wang, Lu Han, Xia Yang, Liu Heliyon Research Article BACKGROUND: The efficacy of therapy in cervical cancer (CESC) is blocked by high molecular heterogeneity. Thus, the sub-molecular characterization remains primarily explored for personalizing the treatment of CESC patients. METHODS: Datasets with 741 CESC patients were obtained from TCGA and GEO databases. The NMF algorithm, random forest algorithm, and multivariate Cox analysis were utilized to construct a classifier for defining the sub-molecular characterization. Then, the biological characteristics, genomic variations, prognosis, and immune landscape in molecular subtypes were explored. The significance of classifier genes was validated by quantitative Real-Time PCR, cell transfection, cell colony formation assay, wound healing assay, cell proliferation assay, and Western blot. RESULTS: The CESC patients were classified into two subtypes, and the high classifier-score patients with significant differences in ECM-receptor interaction, PI3K-Akt signaling pathway, and MAPK signaling pathway showed a poorer prognosis in OS (p < 0.001), DFI (p = 0.016), PFI (p < 0.001) and DSS (p < 0.001), and with high the M0 Macrophage and resting Mast cells infiltration and low HLA family gene expression. Moreover, the constructed classifier owns a high identified accuracy in the tumor/normal groups (AUC: 0.993), the tumor/CIN1–CIN3 groups (AUC: 0.963), and normal/CIN1–CIN3 groups (AUC: 0.962), and the total prediction performance is better than currently published signatures in CESC (C−index: 0,763). The combined prediction performance further indicated that Nomogram (AUC = 0.837) is superior to the classifier (AUC = 0.835) and Stage (AUC = 0.568), and the C−index of calibration curves is 0.784. The potential biological function of classifier genes indicated that silencing GALNT2 inhibited the cancer cell's proliferation, migration, and colony formation; Conversely, the cancer cell's proliferation, migration, and colony formation were increased after the upregulation of GALNT2. The Epithelial-Mesenchymal Transition Experiment showed that GALNT2 knockdown might reduce the levels of Snail and Vimentin proteins and increase E-cadherin; Conversely, the levels of Snail and Vimentin proteins were increased, E-cadherin was reduced by GALNT2 upregulation. CONCLUSION: The classifier we constructed may help improve our understanding of subtype characteristics and provide a new strategy for developing CESC therapeutics. Remarkably, GALNT2 may be an option to directly target drivers in CESC cancer therapy. Elsevier 2023-06-07 /pmc/articles/PMC10360967/ /pubmed/37484385 http://dx.doi.org/10.1016/j.heliyon.2023.e16873 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Mo, XinKai
Wang, Na
He, Zanjing
Kang, Wenjun
Wang, Lu
Han, Xia
Yang, Liu
The sub-molecular characterization identification for cervical cancer
title The sub-molecular characterization identification for cervical cancer
title_full The sub-molecular characterization identification for cervical cancer
title_fullStr The sub-molecular characterization identification for cervical cancer
title_full_unstemmed The sub-molecular characterization identification for cervical cancer
title_short The sub-molecular characterization identification for cervical cancer
title_sort sub-molecular characterization identification for cervical cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360967/
https://www.ncbi.nlm.nih.gov/pubmed/37484385
http://dx.doi.org/10.1016/j.heliyon.2023.e16873
work_keys_str_mv AT moxinkai thesubmolecularcharacterizationidentificationforcervicalcancer
AT wangna thesubmolecularcharacterizationidentificationforcervicalcancer
AT hezanjing thesubmolecularcharacterizationidentificationforcervicalcancer
AT kangwenjun thesubmolecularcharacterizationidentificationforcervicalcancer
AT wanglu thesubmolecularcharacterizationidentificationforcervicalcancer
AT hanxia thesubmolecularcharacterizationidentificationforcervicalcancer
AT yangliu thesubmolecularcharacterizationidentificationforcervicalcancer
AT moxinkai submolecularcharacterizationidentificationforcervicalcancer
AT wangna submolecularcharacterizationidentificationforcervicalcancer
AT hezanjing submolecularcharacterizationidentificationforcervicalcancer
AT kangwenjun submolecularcharacterizationidentificationforcervicalcancer
AT wanglu submolecularcharacterizationidentificationforcervicalcancer
AT hanxia submolecularcharacterizationidentificationforcervicalcancer
AT yangliu submolecularcharacterizationidentificationforcervicalcancer